See more : Catcha Investment Corp (CHAA) Income Statement Analysis – Financial Results
Complete financial analysis of Lixte Biotechnology Holdings, Inc. (LIXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lixte Biotechnology Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Kairuide Holding Co.Ltd (002072.SZ) Income Statement Analysis – Financial Results
- CIL Nova Petrochemicals Limited (CNOVAPETRO.NS) Income Statement Analysis – Financial Results
- VSE Corporation (VSEC) Income Statement Analysis – Financial Results
- Bharat Seats Limited (BHARATSE.BO) Income Statement Analysis – Financial Results
- The New Home Company Inc. (NWHM) Income Statement Analysis – Financial Results
Lixte Biotechnology Holdings, Inc. (LIXT)
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 898.10K | 1.35M | 1.74M | 1.22M | 820.91K | 40.70K | 467.26K | 1.30M | 2.09M | 1.12M | 879.89K | 1.01M | 1.33M | 445.54K | 496.52K | 608.73K | 423.83K | 150.10K | 0.00 |
| General & Administrative | 4.19M | 4.96M | 4.98M | 2.01M | 1.67M | 2.10M | 1.34M | 833.78K | 754.44K | 1.29M | 494.96K | 1.09M | 533.45K | 436.14K | 1.05M | 664.20K | 1.23M | 299.42K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.19M | 4.96M | 4.98M | 2.01M | 1.67M | 2.10M | 1.34M | 833.78K | 754.44K | 1.29M | 494.96K | 1.09M | 533.45K | 436.14K | 1.05M | 664.20K | 1.23M | 299.42K | 32.87K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 33.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 74.00K | 0.00 | 0.00 | 0.00 | 0.00 | 128.00 | 615.00 | 592.00 | 462.00 | 0.00 |
| Operating Expenses | 5.09M | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M | 1.81M | 2.13M | 2.85M | 2.40M | 1.37M | 2.11M | 1.87M | 881.68K | 1.55M | 1.27M | 1.66M | 449.98K | 32.87K |
| Cost & Expenses | 5.09M | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M | 1.81M | 2.13M | 2.85M | 2.40M | 1.37M | 2.11M | 1.87M | 881.68K | 1.55M | 1.27M | 1.66M | 449.98K | 32.87K |
| Interest Income | 1.25K | 11.20K | 626.00 | 5.23K | 49.72K | 4.92K | 1.38K | 183.00 | 78.00 | 66.00 | 3.00 | 8.00 | 125.00 | 1.43K | 155.00 | 3.26K | 10.55K | 11.90K | 0.00 |
| Interest Expense | 0.00 | 8.88K | 7.41K | 3.67K | 0.00 | 4.92K | 1.38K | 183.00 | 78.00 | 66.00 | 3.00 | 8.00 | 125.00 | 1.43K | 1.23K | 1.23K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.09M | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M | 1.81M | 2.13M | 205.77K | 363.11K | 3.00 | 8.00 | 199.84K | 0.00 | 128.00 | 615.00 | 592.00 | 462.00 | 0.00 |
| EBITDA | 3.21K | -1.05K | -7.95K | 1.56K | -2.49M | 4.92K | 1.38K | 183.00 | -2.44M | -2.40M | -1.37M | -3.58M | -1.87M | -881.68K | -1.55M | -1.27M | -1.65M | -561.62K | -32.87K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,220.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.09M | -6.31M | -6.72M | -3.27M | -2.49M | -2.14M | -1.81M | -2.13M | -2.65M | -2.40M | -1.37M | -2.11M | -1.87M | -881.68K | -1.55M | -1.27M | -1.66M | -499.98K | -32.87K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,323.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.21K | -1.05K | -7.95K | 1.56K | 49.72K | 4.92K | 1.38K | 183.00 | -205.70K | -363.05K | 3.00 | -1.47M | -199.71K | 1.43K | -1.08K | 2.03K | 10.55K | -38.10K | 0.00 |
| Income Before Tax | -5.09M | -6.31M | -6.73M | -3.26M | -2.44M | -2.13M | -1.81M | -2.13M | -2.85M | -2.77M | -1.37M | -3.58M | -2.07M | -880.25K | -1.55M | -1.27M | -1.65M | -488.08K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,426.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.82K | 6.79K | -1.56K | -49.72K | -9.85K | -1.81K | -2.13K | -78.00 | -66.00 | 0.00 | -8.00 | -125.00 | 0.00 | 0.00 | 0.00 | 0.00 | 38.10K | 32.87K |
| Net Income | -5.09M | -6.30M | -6.74M | -3.26M | -2.39M | -2.13M | -1.81M | -2.13M | -2.85M | -2.77M | -1.37M | -3.58M | -2.07M | -880.25K | -1.55M | -1.27M | -1.65M | -488.08K | -32.87K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,426.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.66 | -39.85 | -5.00 | -2.89 | -2.14 | -2.18 | -1.94 | -2.68 | -3.66 | -3.74 | -1.98 | -5.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.66 | -39.85 | -5.00 | -2.89 | -2.14 | -2.18 | -1.94 | -2.68 | -3.66 | -3.74 | -1.98 | -5.51 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 1.91M | 158.20K | 1.35M | 1.13M | 1.12M | 979.94K | 930.00K | 797.00K | 779.00K | 740.00K | 693.00K | 649.00K | 586.16M | 578.94M | 488.64M | 465.41M | 445.13M | 379.17M | 45.00M |
| Weighted Avg Shares Out (Dil) | 1.92M | 158.20K | 1.35M | 1.13M | 1.12M | 979.94K | 930.29K | 797.93K | 779.89K | 740.09K | 693.05K | 649.76K | 586.16M | 578.94M | 488.64M | 465.41M | 445.13M | 379.17M | 45.00M |
Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference
Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte's Lead Compound LB-100 to Treat Small Cell Lung Cancer
WestPark Capital Announces Closing of $5,700,000 Follow-On Offering and NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT, LIXTW)
Calyxt Launches New Website Showcasing the Power and Possibilities of Plants
Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014
Source: https://incomestatements.info
Category: Stock Reports